Danaher Details Multi-Year Expansion Plan as Cepheid Cuts 67 Roles
Danaher has outlined a multi-year plan targeting high-single-digit expansion beyond 2027, while its Cepheid subsidiary prepares to eliminate 67 positions in California by late December.
Danaher Corporation is pursuing a long-term growth agenda while making workforce adjustments in its diagnostics business. Speaking at the UBS Global Healthcare Conference on Monday, November 9, Chief Executive Julie Sawyer Montgomery outlined a strategy to accelerate beyond the company's current mid-single-digit base, Investing.com reported. Management designated 4% to 5% core growth, excluding respiratory revenue, as the initial benchmark for 2027, with longer-term goals aimed at reaching high-single-digit expansion.
The executive pointed to commercial execution, innovation, talent, and capital allocation as the four operational levers supporting the target. The company expects to drive gains through cross-selling across units, wider use of the Danaher Business System, and disciplined mergers and acquisitions. Montgomery noted structural growth opportunities in biologics, biosimilars, artificial intelligence-assisted drug discovery, and blood-based Alzheimer's testing. She added that while bioprocessing reshoring presents upside, the main revenue impact is likely to develop from 2028 onward.
Alongside these projections, Danaher's molecular diagnostics arm, Cepheid, plans to lay off 67 workers at its Sunnyvale, California site by Dec. 28, according to a state Worker Adjustment and Retraining Notification filing. The cuts primarily affect scientists and engineers, with five positions operating remotely. A company representative stated the actions are part of standard business planning to maintain agility and competitiveness across a shifting healthcare environment.
Cepheid's workforce reductions follow earlier cuts of more than 1,300 California positions across 2023 and 2024, along with 167 positions targeted last year as post-pandemic respiratory test demand normalized. Danaher projects flat core diagnostics revenue growth in fiscal 2026, excluding respiratory testing, following 1.5% growth in 2025. Still, management noted that Cepheid continues expanding at a double-digit rate when excluding respiratory diagnostics, supported by third-quarter equipment order gains in units like Cytiva.
In executive transactions, Executive Vice President Matthew McGrew exercised 17,385 stock options at an exercise price of $88.24 per share on November 9, 2026, according to a Form 4 filing. McGrew sold all 17,385 shares the same day at a weighted average price of $235.6889, leaving him with 12,674 directly held shares and 10,293.503 shares held indirectly through a 401(k) plan.